findmyKOL

Sham Mailankody, MBBS

Basic profile

Memorial Sloan Kettering Cancer Center

ORCIDNPI
RegionNew York, NY · NortheastSpecialtyMedical OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH funding2019–2020

Sham Mailankody is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 455 publications with 8,797 citations (h-index 48); ClinicalTrials.gov lists 6 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
455publications

Distinct works indexed by OpenAlex, matched via ORCID.

8,797citations

Total citations across indexed works.

48h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2019–2020

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1275 York Ave
New York, NY 100656007

Telephone

646-608-3712

Provider last certified this registry record 7 May 2025.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Dermatology

    33%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33%
    Acyclovir100%
    Part D48 patients
  • Metabolism & gastrointestinal

    16.1%
    Proton pump inhibitor12.6%
    Omeprazole73%Pantoprazole Sodium27%
    Part D<11 patients
    Serotonin-3 Receptor Antagonist3.4%
    Ondansetron Hcl100%
    Part D<11 patients
  • Cancer & immunology

    12.6%
    Thalidomide Analog12.6%
    Lenalidomide51%Revlimid33%Pomalyst16%
    Part D<11 patients
Where care is delivered (Part B)13.8% facility · 86.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20192020 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”